U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H16N2S.C4H6O6
Molecular Weight 370.421
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MORANTEL TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCCN=C1\C=C\C2=C(C)C=CS2

InChI

InChIKey=GGXQONWGCAQGNA-UUSVNAAPSA-N
InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/b5-4+;/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Description

Morantel (1,4,5,6-tetrahydro-1-methyl-2-[2-(3-methyl-2-thienyl)ethenyl pyrimidine) is a tetrahydro-pyrimidine anthelmintic, differing from the related analogue pyrantel by the presence of a methyl group on the thiophene ring. Morantel tartrate, manufactured by Pfizer, Inc., was approved in the United States for use in cattle in 1981, and entered the market in early 1982. Three formulations have been approved in the United States: RUMATEL® Medicated Premix-88; RUMATEL Cattle Wormer Bolus, and PARATECT FLEX™ Diffuser, a sustained release bolus. It is intended to treat roundworms and tapeworms. Morantel is administered in lactating and non lactating cattle as morantel tartrate as a slow-release bolus (11.8 g morantel base per animal) or as a single oral dose of 6 to 7.5 mg morantel base/kg bw and in pigs at a single dose equivalent to 7.5 mg base/kg bw. In sheep, the citrate salt is administered at a single dose equivalent to 5 to 6 mg morantel base/kg bw. Morantel acts as a potent agonist at the acetylcholine receptors on the muscle cells of nematodes. Activation of the acetylcholine receptors induces a prolonged, spastic paralysis of the worms and expulsion from the host. It also been reported to block neurotransmission in vertebrates, to possess nicotine-like properties and to mimic acetylcholine at receptors in autonomic ganglia, adrenal medullae and respiratory tissues. Morantel and its salts are not used in human medicines.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.96 µM [IC50]
60.0 µM [EC50]
29.0 µM [EC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Rumatel

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Morantel is administered in lactating and non lactating cattle as morantel tartrate as a slow-release bolus (11.8 g morantel base per animal) or as a single oral dose of 6 to 7.5 mg morantel base/kg bw and in pigs at a single dose equivalent to 7.5 mg base/kg bw. In sheep, the citrate salt is administered at a single dose equivalent to 5 to 6 mg morantel base/kg bw.
Route of Administration: Other
In Vitro Use Guide
When the nematodes (Heligmosomoides polygyrus) were incubated in vitro with morantel (MRT) at concentrations from 1 mM to 10 nM, in RPMI medium for 2 or 6 h and then transferred to a drug-free medium (RPMI medium supplemented with 0.5% BSA) for 24 h or continuously exposed to the drug in supplement-free medium (24 h), the concentration- and time-dependent inhibitory effect on AChE secretion was observed. The concentration inhibiting the secretion of AChE by 50% (IC50) relative to drug-free controls was estimated to be 2.96 uM.